Clinical Characterization of Patients with Chronic Spontaneous Urticaria According to Anti-TPO IgE Levels
Overview
Affiliations
Background: Chronic spontaneous urticaria (CSU) is a heterogeneous disease with some frequent comorbidities like autoimmune diseases, drug reactions, and inducible urticaria. IgE antibodies against thyroid peroxidase (anti-TPO IgE) could be associated with some of these clinical characteristics.
Objective: To explore the clinical characteristics of CSU patients, according to the presence of anti-TPO IgE in serum.
Methods: Anti-TPO IgE levels were measured during the clinical control period (Urticaria Activity Score, 0 point) and exacerbation period (≥3 points) in 100 CSU patients. Patients with self-reported exacerbation of skin involvement by foods, nonsteroidal anti-inflammatory drugs (NSAIDs), and physical triggers underwent controlled challenge tests.
Results: We identified 2 groups of patients: (1) patients with anti-TPO IgE during the clinical control period or during an exacerbation, who had a higher frequency of atopy, asthma, and positive challenge test results with NSAIDs and (2) patients without anti-TPO IgE during any period, who had a higher frequency of positive challenge test results for inducible urticaria. Among the first group (anti-TPO IgE at any point), we identified 3 subgroups: patients with anti-TPO IgE during the clinical control period ( = 12); patients with anti-TPO IgE during the clinical control period and significantly increased levels during an urticaria exacerbation ( = 18); and patients with anti-TPO IgE only during an exacerbation ( = 13). None of the patients with self-reported food reactions had a positive challenge test result.
Conclusion: Anti-TPO IgE is a useful biomarker for differentiating between clinical phenotypes of patients with CSU. Elevation of anti-TPO IgE during exacerbation periods supports an association between this autoantibody and the pathogenesis of urticaria.
Jang J, Xiang Y, Yang E, Kim J, Choi B, Park H Allergy Asthma Immunol Res. 2024; 16(6):626-639.
PMID: 39622687 PMC: 11621479. DOI: 10.4168/aair.2024.16.6.626.
Molecular characteristics of atopic dermatitis patients with clinical remission.
Sanchez A, Caraballo A, Alvarez L, Valencia O, Restrepo M, Gaviria R World Allergy Organ J. 2024; 17(11):100983.
PMID: 39534446 PMC: 11555337. DOI: 10.1016/j.waojou.2024.100983.
Research hotspots in urticaria: A bibliometric study of the top 100 most cited articles.
Fu T, Wu Y, Wang R, Liu R, Wen T, Long H Skin Res Technol. 2024; 30(5):e13731.
PMID: 38747942 PMC: 11095479. DOI: 10.1111/srt.13731.
Sanchez J, Jaimes F, Garcia E, Zakzuk J, Cardona R, Velasquez M PLoS One. 2024; 19(2):e0295791.
PMID: 38394074 PMC: 10889609. DOI: 10.1371/journal.pone.0295791.
Atopy in chronic urticaria: an important yet overlooked issue.
Chen Q, Yang X, Ni B, Song Z Front Immunol. 2024; 15:1279976.
PMID: 38380314 PMC: 10876790. DOI: 10.3389/fimmu.2024.1279976.